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Purpose: This study was performed to determine the indications, operative strategy, and 
hemodynamic benefit of redo aortic grafting procedures after earlier excision of an infected 
aortic graft. 
Methods: Among 164 patients treated for aortic graft infection, 15 later underwent redo 
aortic grafting procedures an average of 18 months (range, I to 59 months) after removal 
of an infected aortic graft. Redo grafting procedures were performed for leg ischemia 
(n = 11) or infection (proven, n = 3; suspected, n = 1). The new aortic graft originated 
either from the distal thoracic aorta (n = 5) or from the juxtarenal aortic stump (n = 10). 
Follow-up averaged 56 months (range, 7 to 110 months). 
Results: All patients urvived the redo grafting procedure. In the eleven patients who had 
ischemic symptoms, redo grafting procedures tmiformly resulted in symptomatic improve- 
ment with an increase in ankle-brachial indexes (0.78 + 0.34 vs 0.50 + 0.29; p = 0.02). A 
graft limb occlusion developed in two of these patients (3 and 6 months), but no limbs were 
amputated. In the four patients who had proven or suspected extraanatomic bypass graft 
infection, there was one graft limb occlusion (29 months) and one amputation (17 
months). Overall, recurrent graft infection occurred in three of 15 patients and may be 
more frequent in patients who have a proven extraanatomic bypass graft infection (2 of 3 
vs 1 of 12; p -- 0.08). Infection accounted for two of the three graft limb occlusions and 
two of the three late deaths. Recurrent infection was not associated with early (<1 year) 
regrafting procedures, and culture results did not correlate with the microbiologic features 
of the primary infection. 
Conclusions: Redo aortic grafting procedures can be performed safely and at relatively early 
intervals (6 to 12 months) after emoval of the infected aortic graft. The procedure reliably 
relieves ischemic symptoms of the hemodynamically inadequate xtraanatomic bypass 
graft. Reinfection remains a risk after redo aortic grafting procedures, particularly when 
treating established extraanatomic bypass graft infection. (J Vasc Surg 1996;24:328-37.) 
The traditional management of aortic graft infec- 
tion requires infected graft removal and an extraana- 
tomic bypass (EAB) grafting procedure, usually with 
staging. 1-9 Because of the improved patient survival 
rates that accompany this treatment strategy, an 
increasing number of patients rely on the continued 
function of the EAB grafts for leg per fusion. EAB 
grafts traditionally are less durable than in situ aortic 
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grafts, I°-13 especially when placed under the adverse 
conditions that are present during the treatment of 
aortic graft infection. The perfused limbs are at risk 
because of EAB graft thrombosis, hemodynamic 
insufficiency, or infection. 
Treatment of the failed EAB graft becomes in- 
creasingly difficult as inflow and outflow potential are 
limited and limb perfusion is easily compromised. 
Reluctance to reuse the native aorta, which offers the 
best inflow source for leg revascularization, is the 
result of  extensive scarring of the retroperitoneum 
and the risk of placing a prosthesis in a previously 
infected field. Reported experience of reoperative 
aortic grafting procedures in survivors of aortic graft 
infection has offered limited guidelines for placement 
of these grafts back into the previously infected 
bedJ 4-21 
The purpose of this review is to determine the 
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Table I. Treatment of original aortic graft infections 
Graft excision, Days of intravenous 
Patient no. Type Culture result revaseularization antibiotics 
1 PGI Salmonella EAB Unknown 
2 PGI S. epidermidis, Enterococcus TEA 7 
3 PGI Diphtheroids TEA 7 
4 AEF None obtained EAB 1 
5 AEF Bacteroids, Streptococcus EAB 14 
6 AEF E. coli EAB 13 
7 AEF S. aureus, Diphtheroids, E. coli EAB 10 
8 AEF No growth None 10 
9 AEF P. aches EAB 14 
10 AEF Unknown EAB Unknown 
11 PGI P aches EAB 10 
12 PGI S. aureus EAB 27 
13 PGI S. epidermidis EAB 10 
14 PGI Xanthomonas maltiphia EAB 14 
15 PGI Streptococcus EAB 14 
PGI, Prosthetic graft infection; AEF, aortoenteric fistula; EAB, extraanatomic bypass; TEA, thromboendarterectomy. 
indications for operation, the operative strategies 
used, and the early and late results of redo aortic 
grafting procedures after previous treatment of an 
infected aortic graft. 
PATIENTS AND METHODS 
Between 1963 and 1993, 164 patients were 
treated at the University of California, San Francisco 
for aortic graft infection, including 71 procedures for 
aortoenteric fistulas and 93 for prosthetic graft infec- 
tions. Fifteen of these patients (9%), nine men and six 
women, underwent redo aortic grafting procedures 
for leg ischemia or EAB graft infection and are the 
subject of this report. Patient and follow-up data were 
obtained by review of the hospital charts and office 
and referring physician records. 
Indications for the original aortic graft procedure 
in these fifteen patients included aneurysmal disease 
in seven patients and occlusive disease in eight. The 
original grafts were bifemoral in nine patients, biiliac 
in five, and an aortic tube in one, most often with an 
end-to-end proximal anastomosis ( 13 of 15). 
The original aortic graft infections included seven 
aortoenteric fistulas and eight prosthetic graft infec- 
tions, occurring an average of 56 months (range, 4 to 
140 months) after the initial aortic graft placement 
(Table I). Culture data from the original infection 
were available for 14 of the patients: 11 had positive 
results, one had a negative result, and two had 
indeterminate r sults. Treatment of each of these 
infections included total graft removal and a course of 
intravenous antibiotics for as many as 4 weeks (mode, 
14 days; median, 12 days). Leg revascularization was 
accomplished by EAB graft implantation i  12 pa- 
Table II. Complications involving EAB 
(n = 12) and their treatment 
Procedures 
before redo 
Complication Occurrences Patients aortic grafting 
Occlusions 6 3 5 
Hemodynamic failure 8 3 8 
Prosthetic infection 4 3 1 
Seroma formation 1 1 0 
Limb amputation 3 2 3 
Total 22 9 individuals 17 
tients and by aortoiliac thromboendarterectomy in 
two; it was considered unnecessary in one patient. 
In the 12 patients who had a leg revascularized 
with" an EAB graft, a total of 22 complications 
occurred before redo aortic grafting procedure, in- 
cluding six occlusions, eight hemodynamic failures, 
four prosthetic graft infections, one seroma forma- 
tion, and three amputations (Table 1I). Seventeen 
procedures were performed in nine of these patients 
to correct EAB graft failure or infection. 
Indications for redo grafting procedures included 
ischemic symptoms in 11 patients, a proven EAB graft 
infection in three, and a chronic graft seroma, sus- 
pected to be infected, in one (Table 11I). The average 
age of the patients at the time of the regrafting 
procedure was 64 years (range, 42 to 78). The interval 
between the removal of the original infected aortic 
graft and the placement of the new aortic graft 
averaged 18 months (range, 1 to 59; median, 13). 
Two grafts (patient numbers 3 and 4) were placed 
within 6 months after removal of the infected graft, 
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Table III. Details of redo aortic grafting procedure (n = 15) 
Patient no. Operative indications 
Status of EAB Interval before Proximal Perioperative 
at time infection and aortic antibiotics 
of redo redo (mo) anastamosis (days) 
Patients with ischemic symptoms 
1 Claudication * Patent 
2 Claudication None 
3 Rest pain None 
4 Rest pain Patent 
5 Rest pain* Occluded 
8 Claudication None 
11 Claudication* Patent 
12 Claudication Patent 
13 Rest pain Patent 
14 Rest pain* Occluded 
15 Claudication Patent 
Patients with proven/suspected EAB infection 
6 Infection (Staph epidermidis) Patent 
7 Seroma (chronic) Patent 
9 Infection (Staph epidermidis) Patent 
10 Infection (no growth) Patent 
30 Thoracic 6 
10 Infrarenal 7 
1 Thoracic 24 
6 Thoracic 3 
10 Thoracic 7 
10 Infrarenal 7 
15 Infrarenal 3 
10 Thoracic 7 
25 Infrarenal Unknown 
11 Infrarenal 6 
15 Infrarenal 4 
35 Infrarenai 10 
22 Infrarenal 5 
13 Infrarenal 7 
59 Infrarenal 22 
*Multiple EAB occlusions. 
and seven of the 15 patients underwent redo aortic 
infection. In patients in whom the redo grafting 
procedure was performed for EAB graft infection, the 
prosthetic bypass graft was completely removed either 
at the time of redo surgery (two) or within several days 
(two). 
The redo aortic graft originated from the infrare- 
nal position in 10 patients and from the descending 
thoracic aorta in the remaining five (Table III). Figs. 
1 and 2 illustrate the techniques that were used for 
creation of these proximal anastomoses. Postopera- 
tive arteriograms are demonstrated in Fig. 3. The 
location of the distal anastomosis was the terminal 
aorta in one patient, the lilac arteries in two, the 
femoral bifurcation in six, and a patent uninfected 
prosthetic segment attached to the femoral artery in 
six. Concomitant procedures were performed in only 
one patient (number 13), who underwent transaortic 
bilateral renal endarterectomy. At the time of the 
reimplantation, the retroperitoneum was either clini- 
cally uninfected, culture negative, or both. Periopera- 
tive antibiotics were administered for a median time of 
7 days (range, 3 to 24). 
The statistical analysis was performed with Fish- 
er's exact test and Student's paired t test, where 
appropriate. The numeric values are reported as the 
mean plus or minus the standard eviation. 
RESULTS 
All 15 patients urvived redo aortic grafting pro- 
cedures and were available for long-term follow-up, 
which averaged 56 months (range, 7 to 110 months; 
median, 48 months). Table IV summarizes the results 
of the procedures performed in patients who had leg 
ischemia or EAB graft infection in terms of graft 
patency, late amputation, recurrent graft infection, 
and survival. 
Perioperative complications. Two patients 
(numbers 5 and 6) had an intraoperative complica- 
tion: an incidental enterotomy and a splenic injury 
requiring asplenectomy. In the perioperative period, 
five of the 15 patients had a total of five complications: 
pulmonary (2), renal (1), graft thrombectomy (1), 
and groin wound infection (1). All patients left the 
hospital with a patent graft. 
Patients treated for ischemic symptoms. Eleven 
patients underwent redo grafting procedures for 
ischemic symptoms (Table IV). Each patient either 
had relief of preoperative r st pain or had subjective 
improvement of claudication symptoms. At long- 
term follow-up, eight of the 11 patients remained 
asymptomatic, whereas the rest had stable and im- 
proved claudication without rest pain. Nine of eleven 
grafts remained patent throughout he follow-up 
period. Two occlusions occurred, at 3 and 6 months 
after surgery. A thrombectomy was performed in one 
graft; it remained patent at follow-up. The other was 
caused by a culture-negative recurrent graft infection 
7 months after the redo aortic grafting procedure. 
This graft had been placed 15 months after treatment 
of an aortoenteric fistula; the results of the culture 
were positive for Propionibacterium acnes (Table I). 
The treatment of the recurrent infection involved in 
situ regrafting and chronic antibiotic suppression, and 
was successful. This patient represented the only 
recurrent infection in this group. No revascularized 
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Fig. 1. Circumferential mobilization of pararenal orta (left), reopening of infrarenal stump 
(middle), and end-to-end anastomosis with prosthetic aortic graft (right). Division of left renal 
vein may facilitate exposure, but is not routinely performed. Reanastomosis of this vein is not 
necessary if adequate collateral outflow is present. 
Fig. 2. Illustration of beveled end of prosthetic aortic graft attached to lateral supraceliac 
aortotomy. 
limbs in this group were amputated during follow-up; 
the above-knee amputation performed in patient 3 
involved alimb that was not revascularized as a result 
of occluded istal vessels. 
Patients with EAB graft infection (proven or 
suspected). Four patients underwent reoperation for 
EAB graft infection: three proven and one suspected 
(seroma) (Table IV). Two of the four patients (num- 
bers 6 and 7) have a functioning, noninfected in-line 
aortic graft at 41 and 81 months after the regrafting 
procedure. Recurrent aortic graft infection developed 
in the other two patients. Patient 9 was asymptomatic 
for 16 months after surgery until a prosthetic-colonic 
fistula developed. The patient's left graft limb eroded 
into the sigmoid colon, and she sustained a septic 
embolus to her left leg that necessitated an amputa- 
tion shortly before her death. The original retroperi- 
toneal infection was a P. acnes aortoenteric fistula 
(Table I). Patient 10 had a culture-negative prosthetic 
graft infection that occurred 29 months after the redo 
aortic grafting procedure. After the graft was removed 
and an ascending aortofemoral bypass performed, the 
patient survived 40 additional months, but died from 
sepsis. Culture results of her original graft infection 
are unknown. When the incidence of recurrent aortic 
graft infection in patients who underwent reoperation 
for known EAB graft infection (2/3) is compared 
with that in patients who underwent reoperation 
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Fig. 3. Postoperative angiograms of patent redo aortic grafts originating from infrarenal stump 
(left), and supraceliac aorta (right), which takes a more lateral course. 
Tab le  IV.  Long- term results o f  redo aortic grafting (n = 15) 
Redo aortic graft Recurrent graft 
Patient no. patency Limb salvage infection Current status 
Patients with ischemic symptoms 
1 Patent Yes No Asymptomatic 
2 Patent Yes No Improved 
3 Patent AKA, 1 mo No Asymptomatic 
4 Patent Yes No Improved 
5 Patent Yes No Improved 
8 Patent Yes No Asymptomatic 
11 Occluded, 6 mo Yes PGI, 7 mo Asymptomatic 
12 Patent Yes No Asymptomatic 
13 Patent Yes No CVA, 41 mo 
14 Occluded, 3 mo Yes No Asymptomatic 
15 Patent Yes No Asymptomatic 
Patients with proven/suspected EAB infection 
6 Patent Yes No Asymptomatic 
7 Patent Yes No Asymptomatic 
9 Patent BKA, 17 mo AEF, 16 mo Dead, 18 mo 
10 Occluded, 29 mo Yes PGI, 29 mo Dead, 69 mo 
AICA, Above-knee amputation; BKA, below-knee amputation; PGI, prosthetic graft infection; AEF, aortoenteric f stula. 
wi thout  proven infection (1 /12) ,  the difference al- 
most reaches statistical significance (p = 0.08, Fish- 
er's exact test). 
Hemodynamie  improvement .  Preoperative and 
postoperative anlde-arm indices were available for a 
total o f  14 l imbs (Table V). Patients who were 
treated for ischemia had an average preoperative 
ABI  o f  0.50 + 0.29, which improved to 0.78 + 0.34 
(p = 0.02). A significant increase was also seen in 
patients who did not  have ischemic symptoms, from 
0.83 + 0.15 to 1.06 + 0.12 (p = 0.002). 
Late  survival .  At  the t ime of  fol low-up, 12 of  15 
patients remained alive with a functioning raft free o f  
infection (Table IV). Two late deaths occurred in the 
group treated for EAB graft infection and were caused 
by recurrent infection. The third death was related to 
a cerebrovascular ccident. 
D ISCUSSION 
Prosthetic graft infection remains one o f  the most 
devastating complications that can occur after aortic 
surgery. The reported treatment outcomes,  however, 
have improved over the past decade. Before 1980, the 
reported mortal i ty rate ranged from 35% to 75%, with 
amputat ion rates as high as 37% sometimes re- 
ported.  22-26 Since then, mortal i ty rates consistently 
have been lower than 50%, with some larger series 
report ing mortal i ty rates as low as 14%. 1-9'27 The 
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Table V. Summary of hemodynamic data (14 limbs) 
Before surgery 
Ankle-arm index (average +-standard deviation) 
After surgery Change p 
Ischemic limbs (8) 0.53 -+ 0.29 
Nonischemic limbs (6) 0.83 _+ 0.15 
Total limbs (14) 0.67 _+ 0.27 
0.82 +__ 0.35 0.29 __+ 0.29 0.04 
1.06 -+ 0.12 0.23 __+ 0.10 0.002 
0.93 + 0.29 0.26 -+ 0.22 0.002 
concomitant amputation rates, however, remain as 
high as 31%) 7 
With improved survival rates, more patients rely 
on an alternative form of leg revascularization that 
may not provide adequate, durable blood flow for 
their life span. Revascularization f the leg typically is 
provided by an EAB graft that originates from the 
axillary artery and terminates in the femoral or distal 
extremity arteries; contralateral limb perfusion is 
maintained by a femorofemoral graft. Reported pa- 
tency and limb salvage rates for elective primary EAB 
grafts may be acceptable, 1°'~2 but when they are used 
to circumvent aortic graft infection to provide leg 
perfusion, they are frequently suboptimal, z'a'<s 
The indications for perative management of EAB 
graft failure in a patient with a previously treated graft 
infection include hemodynamic failure (thrombosis 
or poor graft flow) or graft infection (proven or 
suspected when perigraft fluid appears). Operative 
management can be difficult because multiple revi- 
sions may be necessary to maintain function. The 
primary EAB graft patency rate in patients who are 
treated for aortic graft infection has been reported as 
low as 43% at 3 years? Similarly, multiple procedures 
may be necessary to remedy EAB graft infection, 
commonly reported in as many as 22% of patients. 5 
Failure oft:he EAB graft was common among our own 
patients before they underwent the redo aortic graft- 
ing procedure. A total of 22 complications occurred 
in the 12 patients who had an EAB graft placed as part 
of their treatment of aortic graft infection. Nine of 
these patients underwent 17 operations, including 
three amputations, before the redo aortic grafting 
procedure. These figures clearly attest to the inherent 
difficulties of maintaining an EAB graft for the life of 
the patient who has had a treated graft infection. 
The objective of our treatment was to reestablish 
inflow from the native aorta by using a standard 
bifurcation prosthesis. One third of the patients (5) 
had the graft attached to the side of the distal thoracic 
aorta through combined thoracoabdominal p- 
proaches (4) or transabdominal medial visceral rota- 
tion (1). The other two thirds of the patients (10) had 
the aortic stump reopened and the graft attached to 
the end of the subrenal aorta with the transabdominal 
(7), retroperitoneal (2), or thoracoretroperitoneal (1) 
approaches. Transabdominal exposures were made 
either with traditional infracolic approaches (5) or 
with left medial visceral rotation (2). The graft limbs 
were attached to 15 native arteries and eight residual 
uninfected patent prosthetic segments that were al- 
ready attached to he common femoral artery. 
The operative mortality rate for both approaches 
to the aorta in this series was zero. The distal thoracic 
aorta has been used as a site from which to originate 
an aortic graft for edo reconstructions with a low 
mortality rate, but experience in patients who have 
had previous aortic graft in ection is limited. 14-18,21'28 
This exposure allows the physician to avoid perform- 
ing the operation in a potentially scarred field and uses 
a segment of aorta that is rarely involved with occlu- 
sive disease, but may contribute to respiratory com- 
plications, as seen in one of our patients. This ap- 
proach allows routing of the graft limbs away from the 
previously infected field, thus circumventing the 
problem of possible residual retroperitoneal contami- 
nation. 
Grafting to the juxtarenal aortic stump in a previ- 
ously infected field was successful in all 10 patients in 
whom it was performed. The procedure requires 
temporary suprarenal aortic clamping to facilitate 
end-to-end grafting to the juxtarenal aorta. One 
significant echnical complication occurred in the 
only patient in this series who had severe pararenal 
atherosclerosis: a transaortic endarterectomywas nec- 
essary to establish a patent aortic stump, which led to 
a unilateral renal rtery occlusion and required a 
thrombectomy after surgery. Although not enough 
hemodynamic data are included in this report o allow 
these two approaches to be compared irectly, the 
infrarenal approach offers an in-line revascularization 
procedure, which in the presence of severe aortic 
atherosclerosis may prevent further aortic thrombo- 
sis. 29 This method of reconstruction is currently our 
favored approach. 
A major concern of redo aortic grafting proce- 
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dures is the timing of the reoperation i relation to the 
removal of the previously infected prosthesis. In 
1983, Fulenwider et al.20 reported three patients who 
underwent placement of a retroperitoneal graft a 
minimum of 2 years after septic graft removal. He 
reported no reinfections, with a minimum follow-up 
of 1 year. In our 1984 series, Reilly et al.19 stlggested 
that 6 to 12 months was probably sufficient to avoid 
reinfection in the absence of evidence that suggests 
ongoing retroperitoneal sepsis. Our current, updated 
report supports this view. Recurrent infection has not 
developed in any of the seven grafts that were placed 
within 1 year of the original infection, and no corre- 
lation between the grafting interval and recurrent 
infection could be made. 
Although the timing of the regrafting procedure 
may be important, one must consider the micro- 
biologic features of the original infection. Of the 
seven grafts that were placed within 1 year of the 
original aortic graft infection, only one was for a 
proven gram-negative infection. We therefore can- 
not generalize that regrafting within I year is safe for 
all types of infections, but we believe that caution is 
necessary when planning a regrafting procedure in 
a patient who survived an aggressive gram-negative 
infection. 
Three of the fifteen grafts, which were placed at 
13, 15, and 59 months after treatment of aortic graft 
infection, did become reinfected. One reinfection was 
caused by late erosion of the graft limb into the distal 
sigmoid colon, which resulted in death at 18 months. 
The two other patients had culture-negative 
infections; one patient is well and remains taking 
suppressive antibiotics, and the other survived for 69 
months after the redo grafting procedure. None of 
the reinfections appear to be directly related to the 
previous retroperitoneal infections by culture result, 
hence it is difficult to conclude that reinfection was 
caused by the presence of continued, subclinical 
retroperitoneal infection. Although the cause of in- 
fection in the patient who had the graft colonic fistula 
is clear, the cause of the other two infections is not. 
One of these patients had a culture-negative EAB 
graft infection, presumably caused by Staphylococcus 
epidermidis, which may have contributed to the 
culture-negative recurrence. 
Although reinfection could not be linked to an 
unsterile retroperitoneum, it was noted that all three 
infections occurred in grafts that were placed in the 
juxtarenal position. Although the groups are small, 
the incidence of reinfection for these grafts (3 of 10) 
was not statistically different from that of grafts that 
originated from the distal thoracic aorta and were 
routed in the far left retroperitoneum (0 of 5; 
p = 0.50). From this experience, we cannot conclude 
that implantation i to the previous graft bed results 
in an increased risk of infection, other than that 
graft-enteric fistula is more probable solely on the 
basis of graft location. Furthermore, a direct com- 
parison between the two groups may be unfair be- 
cause all four patients who had proven or suspected 
EAB graft infection were treated with an infrarenal 
graft. 
The purpose of the redo aortic grafting proce- 
dure is twofold: to improve blood flow for patients 
who have ischemic legs or to create a durable, 
less-susceptible alternative conduit for those who 
have an EAB graft infection. The results clearly show 
that these redo aortic grafts did improve distal 
perfusion--all 11 patients who underwent redo 
grafting procedures for ischemic symptoms had relief 
or improvement of their preoperative symptoms. 
These results appear durable as wc!l , as eight of the 
11 remained asymptomatic at the time of long-term 
follow-up and the other three remained stable. Over- 
all, three of 15 grafts occluded during follow-up; 
however, two were related to recurrent graft infec- 
tion. A successful thrombectomy was performed in 
the third occlusion, which has remained patent for 
14 additional months. In addition, the limb salvage 
rate in the 11 patients who underwent redo aortic 
grafting procedures for the relief of distal ischemia 
was excellent, with no amputation of any revascu- 
larized limbs. The only amputation in this group 
involved previous unreconstructible disease in a limb 
that was deemed unsalvageable. 
The hemodynamic efficacy of these grafts was 
confirmed by a significant improvement in the ankle- 
arm indexes after surgery. Although it is not surprising 
that the indexes of patients who have failing (or failed) 
reconstructions should be improved after edo aortic 
grafting procedures, we found that patients without 
ischemic symptoms and a functioning EAB graft also 
had improvement in the anlde-arm indices after sur- 
gery. This improvement is caused by reestablishment 
of in-line, unimpeded aortic blood flow. 
No data yet exist on the prophylactic use of redo 
aortic grafting procedures. This series showed that 
this procedure yielded a significant improvement in
limb per fusion when compared with the original EAB 
graft. Therefore, in selected patients who have a 
potentially threatened EAB graft, prophylactic redo 
aortic grafting procedures may be justified despite a 
lack of ischemic symptoms. 
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CONCLUSION 
The definitive treatment for 15 survivors of pre- 
vious aortic graft infection involved redo grafting 
procedure.s from the native aorta for ischemic or 
infectious complications of EAB grafts. The redo 
aortic grafting procedure provided safe, durable re- 
perfusion in the legs of our patients. For patients who 
underwent reoperation for ischemic symptoms, the 
procedure provided uniform and long-term symptom 
relief. For patients who had proven or suspected EAB 
graft infection, the redo grafting procedure provided 
a durable, alternative conduit for limb perfusion, 
although this population appeared to have a higher 
incidence of recurrent graft infection. 
The safety of redo grafting procedures in our series 
and the low risk of ischemia or septic complications 
observed in our patients during long-term follow-up 
support our recommendation that this treatment be 
offered w]henever the EAB graft fails. When infection 
of the EAB graft occurs, the redo aortic grafting 
procedure should be carefully considered, and all 
reasonable attempts to clear the infection should be 
made befbre replacement of the aortic graft. This 
strategy reestablishes the aortofemoral graft, which 
markedly reduces the risks of a symptomatic EAB 
graft and, importantly, improves the quality of the 
patient's subsequent life. 
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DISCUSSION 
Dr. G. Patrick Clagett (Dallas, Tcx.). I congratulate 
the authors on presenting sound and clinically useful data 
that will aid in the'management of this challenging group of 
patients. Their report emphasizcs some of the limitations of 
the use of EAB grafts for this condition. Dissatisfaction with 
EAB grafts has led us to advocate autogcnous reconstruc- 
tion with the superficial femoral popliteal veins or deep 
veins. We are nearing 5-ycars of follow-up in many of these 
patients, and the remarkable thing about hese autogcnous 
reconstructions is their durability. Reinfection is not an 
issuc, and the patency rate is essentially 100%. We and 
others, however, will need to report more complete fol- 
low-up of aortic reconstructions from deep veins, and I 
suspect hat the staged EAB grafting procedure will con- 
tinuc to be the most widely used operation for this problem. 
Thcrcforc, this information from the extensive xperience 
at the University of California, San Francisco is important 
and is somcthing that we all nccd to pay attention to. 
You clearly demonstrate he safety ofrcopcrative aortic 
surgery in this circumstance, specially when the descend- 
ing thoracic aorta is the inflow source. It is of interest that 
these patients underwent many rcoperations in an attempt 
to maintain the patcncy of failing EAB grafts before the 
definitive rcoperation. Do you now have a lower threshold 
for undcrtaldng aortic rcopcration, and what arc your 
eun'ent indications? How many revisions and thrombccto- 
mics of an EAB graft will you allow before recommending 
redo aortic surgery? In a patient with occlusive disease who 
has particularly poor outflow, and in whom the conse- 
quences of a failed cxtraanatomic reconstruction would bc 
disastrous, would you ever recommcnd secondary aorto- 
bifemoral bypass before occlusion or hemodynamic failure 
occur? 
I am also intrigued with your data that suggest an 
increased risk of reinfection when operating on the inffare- 
nal aorta as opposed to the descending thoracic aorta. Do 
you think that this is because of the bacteria that are 
sequestered in these retroperitoneal tissues? If so, how long 
does it take for sterilization of the retroperitoneum to
occur? In your presentation, you mention 6 to 12 months as 
being the minimal safe interval before operation. A few 
patients, however, had new aortic prostheses successfully 
placed at earlier times, and those three who did have 
recurrent aortic graft infections had a prolonged interval of 
greater than 1 year between removal of the first infected 
aortic graft and placement of a new one. Is there an optimal 
time? Does it depend on the organism? And what guidelines 
do you recommend for determining when it is safe to place 
a new aortic prosthesis? 
Again, I commend this report o all. It contains awealth 
of well-documented information from a group that has 
made many contributions to this area. 
Dr. Paul J. DiMuzio. The first questions centered 
around our present indications for performing redo aortic 
grafting procedures under these circumstances. Our study 
predominantly involved symptomatic patients who had 
undergone multiple procedures to correct failing or in- 
fected axillofcmoral bypass grafts. Given what has been an 
overall good outcome for these patients, I think it is 
reasonable to lower the threshold for reestablishing flow 
from the native aorta. The question then becomes whether 
this procedure should be performed prophylactically. Per- 
haps the use of this approach can be considered in patients 
who have fully recovered from their infection and have an 
asymptomatic, hemodynamically compromised bypass 
graft. This seems reasonable given that EAB graft failure in 
this setting frequently occurs suddenly and has dire conse- 
quences. 
The second questions asked how early can redo grafting 
procedures be performed safely without a significant risk of 
infection. Seven of the 15 grafts were placed less than 1 year 
after the initial infection. To date, none of them have 
become reinfected. Two grafts were placed within 6 months 
of infection and were positioned in the retropcritoneum far
to the left. In the infrarenal position, four grafts were placed 
between 6 and 12 months after treatment, and all had 
satisfactory outcomes. Timing, therefore, may not be a 
critical issue if the patient has fully recovered from the 
infection. Furthermore, given that we found no correlation 
between the bacteriologic features of the original graft 
infection and the subsequent recurrences, reinfections may 
in fact have sources other than the retroperitoneum. With 
aggressive debridement and a course of intravenous antibi- 
otics, these infections can be cleared over a course of 
months, and reimplantation may be safe within this time 
period. I would caution, however, that the bacteriologic 
features of the initial infection be considered. Of the seven 
that were reimplanted earlier than 1 year, six were for 
gram-positive infections and one was for a pseudomonal 
infection, reimplanted at10 months. It would be prudent to 
consider how aggressive the original infection was and 
whether a gram-negative organism was involved before 
considering a redo grafting procedure at an early time 
period. 
Dr. Francis Robicsek (Charlotte, N.C.). I have a 
problem understanding that during the time ofreoperafion 
you go back to the same site and then dig in the quagmire 
of the suprarenal aorta--in the middle of scars, with the 
potential that infection may still be present. Why didn't you 
use other "ports," such as the descending or ascending 
thoracic aorta? To me, these are virgin areas and easily 
accessible. This borders on masochism. 
Dr. DiMuzio. Of the 15 grafts placed, five were from 
the supraceliac nd distal thoracic aortas. As you have noted, 
access to this unscarred area may be easier from a technical 
standpoint. Reestablishment of in-line flow from the infra- 
renal aorta may have some theoretic advantages over this 
approach--possibly improved hemodynamics, for example. 
Dr. Stoney has been able to perform this procedure safely, 
and I should note that none of the procedures in which 
placement of an infrarenal aortic graft was planned was 
abandoned for another inflow source. 
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Dr. Dennis F. Bandyk (Tampa, Fla.). You did not 
mention problems with the aortic stump as an indication for 
redo aortic: surgery or as a factor in your operative strategy. 
I have encountered this situation in several patients, and I 
wonder what you would do with a patient in whom you are 
contemplating a redo aortic grafting procedure and in 
whom some dilatation of the aortic stump or thrombus in a 
region of the renal arteries is demonstrated on computed 
tomographic scan. 
Dr. DiMuzio. On reexploration of the renal stump, 
thrombus is a common finding and is a result of the 
remodeling of the ligated aorta. At operation, this throm- 
bus is removed. Of the 15 patients, none had significant 
dilation of the aortic stump. One patient, however, did have 
significant pararcnal atherosclerosis of the pararenal aorta 
and underwent a transaortic endarterecromy. This approach 
allows the opportunity to treat such disease, unlike reestab- 
lishing flow from the supraceliac aorta. 
Dr. John Mannick (Boston, Mass.). I noticed that 
although the procedures you have performed were remark- 
ably successful, the mortality rate from recurrent graft 
infection was 20%. That is a fairly hefty mortality rate. I 
would like you tell us whether or not all these recurrent graft 
infections were in those patients in whom you placed the 
graft in the original bed, that is, the inftarenal end-to-end 
graft in the original bed, or whether you had any deaths 
from recurrent graft infection in those patients in whom the 
proximal anastomosis was placed higher up. 
Dr. DiMuzio. Recurrent graft infection occurred in 
three of the 15 patients. Two of these patients died 18 and 
69 months after the redo grafting procedure, and the third 
patient remains alive at long-term follow-up. Although the 
mortality rate from recurrent infection was approximately 
13%, it should be noted that these deaths occurred late and 
in patients who had EAB graft infections. Clearly this group 
of patients is the most difficult to manage, and overall this 
approach as offered them some chance for cure. 
All three of the reinfections occurred in grafts that were 
placed in the original bed, end-to-end from the inftarenal 
aorta. Although this suggests this graft position poses a risk 
for reinfection, as mentioned, our data suggest hat rein- 
fection comes from sources other than thc previously 
infected retroperitoneum. All four patients who had proven 
or suspected EAB graft infection--clearly a possible source 
of infection--underwent the repeat graft procedure in the 
infrarenal position. Therefore, comparing redo graft posi- 
tion in terms of recurrent infection rate is not possible in this 
selected group of patients. 
Dr. C. Steven Powell (Greenville, N.C.). I would like 
to relate an experience of two episodes of recurrent aor- 
\ 
toenteric fistulas in patients who have had in-line aortic 
grafts placed sometime in the interval after treatment of 
aortic graft infection or aortocnteric fistula. I think this is a 
potential concern with this approach. 
My second question is whether you take any special 
measures to isolate the graft from the duodenum and bowel 
when you perform these redo in-line aortic graft proce- 
dures? 
Dr. DiMuzio. Recurrent aortic enteric fistulae were 
seen in one of our paticnts in whom the graft limbs were 
routed underneath e colon. A colonic fistula occurred and 
ultimately led to the patient's death. We have not seen 
rccurrcnt aortoenteric fistulae involving the duodenum, 
and no special procedures to protect he graft, other than a 
standard reperitonealization, wcrc performed. 
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